Michael Byrnes's Net Worth
$170 Thousand
Who is Michael Byrnes?
Michael Byrnes does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include eFFECTOR Therapeutics, Inc., Ocera Therapeutics, Inc., and CERO THERAPEUTICS HOLDINGS, INC..
SEC CIK
Michael Byrnes's CIK is 0001619893
Past Insider Trading and Trends
2022 was Michael Byrnes's most active year for acquiring shares with 5 total transactions. Michael Byrnes's most active month to acquire stocks was the month of December. 2017 was Michael Byrnes's most active year for disposing of shares, totalling 7 transactions. Michael Byrnes's most active month to dispose stocks was the month of November. 2022 saw Michael Byrnes paying a total of $41,917.52 for 504,966 shares, this is the most they've acquired in one year. In 2017 Michael Byrnes cashed out on 588,600 shares for a total of $247,760.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
eFFECTOR Therapeutics, Inc. (EFTR) Snapshot price: $0.0783
Chief Financial OfficerMichael Byrnes owns 3,117 units of Common Stock which is worth $244.06. From 2021 to 2024 Michael Byrnes acquired a total of 44,658 shares in eFFECTOR Therapeutics, Inc. at a cost of $48,733.75.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +80.17% | 1.39K |
$1.68 | $2,334.32 | 3.12K |
May 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 19
| |||
Form 4
| +11.68% | 4.52K |
$0.50 | $2,249.79 | 43.27K |
Nov 15
| |||
Form 4
| +14.35% | 4.86K |
$0.46 | $2,232.12 | 38.75K |
May 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 17
| |||
Form 4
| +15.91% | 4.65K |
$0.47 | $2,178.53 | 33.88K |
Nov 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
| +590.60% | 25K |
$1.33 | $33,262.50 | 29.23K |
Jun 7
| |||
Form 4
|
∞
| 4.23K |
$1.53 | $6,476.49 | 4.23K |
May 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ocera Therapeutics, Inc. No price found
CFO and TreasurerMichael Byrnes used to own units in Common Stock but no longer holds any shares there. From 2014 to 2017 Michael Byrnes acquired a total of 161,000 shares in Ocera Therapeutics, Inc. at a cost of $29,744.40, Michael also disposed a total of 163,000 shares of Ocera Therapeutics, Inc. equalling to $247,760.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -163.00K |
$1.52 | -$247,760.00 |
0
|
Dec 11
| |||
Form 4
| +1,153.85% | 150K |
—
|
—
| 163K |
Mar 29
| |||
Form 4
| +30.00% | 3K |
$1.28 | $3,854.40 | 13K |
Mar 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
| +53.85% | 3.5K |
$2.07 | $7,245.00 | 10K |
Jan 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
| +62.50% | 2.5K |
$3.61 | $9,025.00 | 6.5K |
May 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 2
| |||
Form 4
| +100.00% | 2K |
$4.81 | $9,620.00 | 4K |
Oct 1
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CERO THERAPEUTICS HOLDINGS, INC. (PBAX) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||